<table id="table5" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5:	Drugs having clinically important interactions with amphetamines.</caption>
<col align="left" valign="top" width="35%"></col>
<col align="left" valign="top" width="65%"></col>
<thead>
<tr>
<th colspan="2" stylecode="Lrule Rrule">
<content stylecode="italics">MAO Inhibitors (MAOI)</content>
</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clinical Impact</td>
<td stylecode="Rrule">MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis.  Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Intervention</td>
<td stylecode="Rrule">Do not administer ADZENYS XR-ODT during or within 14 days following the administration of MAOI [see <content stylecode="italics">
<linkhtml href="#S4">Contraindications (4)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Examples</td>
<td stylecode="Rrule">selegiline, isocarboxazid, phenelzine, tranylcypromine</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold italics">Serotonergic Drugs</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">The concomitant use of ADZENYS XR-ODT and serotonergic drugs increases the risk of serotonin syndrome. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention </td>
<td stylecode="Rrule">Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during ADZENYS XR-ODT initiation or dosage increase. If serotonin syndrome occurs, discontinue ADZENYS XR-ODT and the concomitant serotonergic drug(s) [see <content stylecode="italics">
<linkhtml href="#S5.7">Warnings and Precautions (5.7)</linkhtml>]</content>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold italics">Alkalinizing Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clinical Impact</td>
<td stylecode="Rrule">Increase blood levels and potentiate the action of amphetamine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Intervention</td>
<td stylecode="Rrule">Co-administration of ADZENYS XR-ODT and gastrointestinal alkalinizing agents should be avoided.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Examples</td>
<td stylecode="Rrule">Gastrointestinal alkalinizing agents (e.g., sodium bicarbonate).<br/>Urinary alkalinizing agents (e.g., acetazolamide, some thiazides).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold italics">Acidifying Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clinical Impact</td>
<td stylecode="Rrule">Lower blood levels and efficacy of amphetamines.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Intervention</td>
<td stylecode="Rrule">Increase dose based on clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Examples</td>
<td stylecode="Rrule">Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold italics">Tricyclic Antidepressants</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clinical Impact</td>
<td stylecode="Rrule">May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Intervention</td>
<td stylecode="Rrule">Monitor frequently and adjust or use alternative therapy based on clinical response.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Examples</td>
<td stylecode="Rrule">desipramine, protriptyline</td>
</tr>
</tbody>
</table>